Beijing, China

Haibo Zhao

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Haibo Zhao: Innovator in Pharmaceutical Chemistry

Introduction

Haibo Zhao is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of four patents to his name, Zhao's work is recognized for its potential impact on treating various disorders.

Latest Patents

Zhao's latest patents include innovative compounds known as Imidazo[1,5-a]pyrazine derivatives, which serve as PI3Kδ inhibitors. These compounds are disclosed in a formula that includes stereoisomers and pharmaceutically acceptable salts. The patents also detail methods for treating PI3Kδ related disorders or diseases using these compounds, showcasing Zhao's commitment to advancing therapeutic options.

Career Highlights

Zhao is currently associated with BeiGene, Ltd., a leading biotechnology company focused on molecularly targeted and immuno-oncology drug discovery. His work at BeiGene has positioned him at the forefront of pharmaceutical innovation, contributing to the development of treatments that address critical health challenges.

Collaborations

Zhao collaborates with notable colleagues, including Jing Li and Zhiwei Wang. These partnerships enhance the research and development efforts within his team, fostering an environment of innovation and shared expertise.

Conclusion

Haibo Zhao's contributions to pharmaceutical chemistry through his patents and work at BeiGene highlight his role as a key innovator in the field. His research on Imidazo[1,5-a]pyrazine derivatives exemplifies the potential for new treatments in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…